Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76

PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy. On October 20, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on PTC Therapeutics, Inc. (NASDAQ:PTCT), lifting the price target on the stock to $87 from $76. PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential The analyst cited the solid initial demand for Sephience, which is the company’s newly approved treatment. A notable inter ...